Elusys Therapeutics
Manufacturing · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4 Century Dr Ste 260, Parsippany, New Je...Phone Number
(973) 808-0222Website
www.elusys.comRevenue
$13 MillionIndustry
About Elusys Therapeutics
Elusys Therapeutics specializes in innovative medical countermeasures aimed at providing effective protection against infectious agents and public health threats. The company focuses on the development and commercialization of biodefense solutions, particularly for government partners, and has successfully advanced its product ANTHIM, a monoclonal anthrax antitoxin, to commercial availability. Elusys has secured significant funding from various government agencies to enhance U.S. biosecurity against potential anthrax attacks. Their primary clients include strategic government entities such as the Department of Defense and public health agencies.Explore more
Elusys Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Elusys Therapeutics
Compare insights from companies similar to Elusys Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Elusys Therapeutics Tech Stack
A closer look at the technologies used by Elusys Therapeutics
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Elusys Therapeutics
Sign Up For FreeTo access detailed company insights
Elusys Therapeutics specializes in innovative medical countermeasures aimed at providing effective protection against infectious agents and public health threats. The company focuses on the development and commercialization of biodefense solutions, particularly for government partners, and has successfully advanced its product ANTHIM, a monoclonal... Read More
